ClinicalTrials.gov record
Completed Phase 1 Interventional

A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors

ClinicalTrials.gov ID: NCT00634231

Public ClinicalTrials.gov record NCT00634231. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 18, 2026, 4:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Study identification

NCT ID
NCT00634231
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1
Lead sponsor
Candel Therapeutics, Inc.
Industry
Enrollment
8 participants

Conditions and interventions

Interventions

  • AdV-tk Biological
  • Radiation Radiation
  • valacyclovir Drug

Biological · Radiation · Drug

Eligibility (public fields only)

Age range
3 Years to 21 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 30, 2010
Primary completion
Nov 30, 2015
Completion
May 31, 2021
Last update posted
Aug 24, 2023

2010 – 2021

United States locations

U.S. sites
2
U.S. states
2
U.S. cities
2
Facility City State ZIP Site status
Ann & Robert H. Lurie Children's Hospital of Chicago (Formerly Children's Memorial Hospital) Chicago Illinois 60611
Dana-Farber Cancer Institute Boston Massachusetts 02115

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00634231, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 24, 2023 · Synced May 18, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00634231 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →